204 related articles for article (PubMed ID: 35185871)
1. Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.
Zhang S; Chen YL; Liu CL; Xie JY; Sun BD; Liu DZ
Front Immunol; 2022; 13():757802. PubMed ID: 35185871
[TBL] [Abstract][Full Text] [Related]
2. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis.
Nakanishi Y; Yamaguchi K; Yoshida Y; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Miyamoto S; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Intern Med; 2020 Oct; 59(20):2553-2558. PubMed ID: 32581161
[TBL] [Abstract][Full Text] [Related]
3. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
[TBL] [Abstract][Full Text] [Related]
4. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
Kubeček O; Soukup T; Paulík A; Kopecký J
BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
6. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
7. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
8. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
[TBL] [Abstract][Full Text] [Related]
9. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
10. Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.
Karino K; Fujieda Y; Kawamura T; Abe N; Shimoyama S; Kono M; Kato M; Yasuda S; Atsumi T
Medicine (Baltimore); 2018 Dec; 97(49):e13563. PubMed ID: 30544475
[TBL] [Abstract][Full Text] [Related]
11. Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.
Aritomi T; Kido T; Nakano K; Satoh Y; Noguchi S; Jotatsu T; Hanaka T; Satoh M; Tanaka Y; Yatera K
Intern Med; 2019 Feb; 58(3):427-431. PubMed ID: 30210109
[TBL] [Abstract][Full Text] [Related]
12. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
13. Mapping novel immunogenic epitopes in IgA nephropathy.
Woo SH; Sigdel TK; Dinh VT; Vu MT; Sarwal MM; Lafayette RA
Clin J Am Soc Nephrol; 2015 Mar; 10(3):372-81. PubMed ID: 25542908
[TBL] [Abstract][Full Text] [Related]
14. NanoString technology distinguishes anti-TIF-1γ
Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
[TBL] [Abstract][Full Text] [Related]
15. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
16. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
17. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
18. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
Front Immunol; 2020; 11():625896. PubMed ID: 33613568
[TBL] [Abstract][Full Text] [Related]
19. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
[TBL] [Abstract][Full Text] [Related]
20. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]